• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec11
Crinetics Pharmaceuticals Begins Third Phase Clinical Trial for Atumelnant
21:05
Dec3
Crinetics Pharmaceuticals Begins Phase 1/2 Clinical Trial for CRN09682
13:01
Nov20
Crinetics Pharmaceuticals Launches Phase 3 Clinical Trial for Paltusotine
21:05
Nov10
Cantor Fitzgerald analyst reiterates buy rating on Crinetics Pharmaceuticals
16:48
Nov7
Analyst Maintains Buy Rating on Crinetics Pharmaceuticals
11:56
Crinetics Pharmaceuticals released FY2025 Q3 earnings on November 6 After-Market EST, actual revenue USD 143 K (forecast USD 394 K), actual EPS USD -1.3807 (forecast USD -1.254)
00:00

Schedules & Filings

Schedules
Filings
Nov6
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 143 K, Net Income -130.09 M, EPS -1.3807

Aug7
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 1.031 M, Net Income -115.64 M, EPS -1.2329

May8
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 361 K, Net Income -96.77 M, EPS -1.0394

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
MSOX
7.940
+107.85%
+4.120
YCBD
1.200
+90.17%
+0.569
THH
15.520
+57.72%
+5.680
WEED
25.325
+55.65%
+9.055
NCI
1.920
+54.84%
+0.680
CNBS
34.820
+54.57%
+12.293
MSOS
5.800
+54.26%
+2.040
CGC
1.740
+53.98%
+0.610
RYM
23.800
+47.73%
+7.690
TLRY
12.150
+44.13%
+3.720
View More